PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
November 5, 2016Circulation167 citationsOpen Access

Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College of Cardiology

View Full Paper
DLDonald M. Lloyd‐JonesMHMark D. HuffmanKKKunal N. Karmali

Structured PICO

P
Population
Primary prevention patients (specifically Medicare patients)
I
Intervention
Million Hearts Longitudinal ASCVD Risk Assessment Tool to estimate baseline and updated 10-year ASCVD risk and manage ABCS (aspirin, blood pressure control, cholesterol management, and smoking cessation)
O
Outcome
10-year predicted risk of atherosclerotic cardiovascular disease (ASCVD)

The Million Hearts Longitudinal ASCVD Risk Assessment Tool allows clinicians to estimate updated 10-year ASCVD risk based on adherence to preventive therapies, supporting personalized risk reduction and value-based care.

Abstract

The Million Hearts Initiative has a goal of preventing 1 million heart attacks and strokes-the leading causes of mortality-through several public health and healthcare strategies by 2017. The American Heart Association and American College of Cardiology support the program. The Cardiovascular Risk Reduction Model was developed by Million Hearts and the Center for Medicare & Medicaid Services as a strategy to assess a value-based payment approach toward reduction in 10-year predicted risk of atherosclerotic cardiovascular disease (ASCVD) by implementing cardiovascular preventive strategies to manage the "ABCS" (aspirin therapy in appropriate patients, blood pressure control, cholesterol management, and smoking cessation). The purpose of this special report is to describe the development and intended use of the Million Hearts Longitudinal ASCVD Risk Assessment Tool. The Million Hearts Tool reinforces and builds on the "2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk" by allowing clinicians to estimate baseline and updated 10-year ASCVD risk estimates for primary prevention patients adhering to the appropriate ABCS over time, alone or in combination. The tool provides updated risk estimates based on evidence from high-quality systematic reviews and meta-analyses of the ABCS therapies. This novel approach to personalized estimation of benefits from risk-reducing therapies in primary prevention may help target therapies to those in whom they will provide the greatest benefit, and serves as the basis for a Center for Medicare & Medicaid Services program designed to evaluate the Million Hearts Cardiovascular Risk Reduction Model.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Lloyd‐Jones et al. (2016) studied this question.

synapsesocial.com/papers/6a1d1e8273c56dd1bd2f3687https://doi.org/10.1161/cir.0000000000000467
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Individualized Guidelines: The Potential for Increasing Quality and Reducing Costs2011 · 139 citations
  2. 2Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease2016 · 86 citations
  3. 3Aspirin for the Primary Prevention of Cardiovascular Events: An Update of the Evidence for the U.S. Preventive Services Task Force2009 · 264 citations
  4. 4Effects of Intensive Blood Pressure Lowering on Cardiovascular and Renal Outcomes: A Systematic Review and Meta-Analysis2012 · 780 citations
  5. 5Different Effects of Antihypertensive Regimens Based on Fosinopril or Hydrochlorothiazide With or Without Lipid Lowering by Pravastatin on Progression of Asymptomatic Carotid Atherosclerosis2004 · 156 citations